NASDAQ:KOOL - Cesca Therapeutics Stock Price, Forecast & News

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

Cesca Therapeutics Inc (NASDAQ:KOOL) issued its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative return on equity of 77.30% and a negative net margin of 98.84%. View Cesca Therapeutics' Earnings History.

Cesca Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Cesca Therapeutics.

1 analysts have issued 1 year target prices for Cesca Therapeutics' stock. Their forecasts range from $7.50 to $7.50. On average, they anticipate Cesca Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 88.4% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.

News stories about KOOL stock have been trending very negative on Saturday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cesca Therapeutics earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cesca Therapeutics.

Some companies that are related to Cesca Therapeutics include Tocagen (TOCA), Aquabounty Technologies (AQB), Vita Life Sciences (VLS), Bellerophon Therapeutics (BLPH), NF Energy Saving (BIMI), Respiri (RSH), Actinium Pharmaceuticals (ATNM), Viridium Pacific Group (VIR), Anteo Diagnostics (ADO), Sernova (SVA), AquaBounty Technologies (AQB), Mannatech (MTEX), Polarityte (PTE), Kazia Therapeutics (KZA) and Arch Therapeutics (ARTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Synergy Pharmaceuticals (SGYP), AEterna Zentaris (AEZS), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI) and Amicus Therapeutics (FOLD).

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KOOL stock can currently be purchased for approximately $3.98.

Cesca Therapeutics has a market capitalization of $9.63 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.View Additional Information About Cesca Therapeutics.

The official website for Cesca Therapeutics is http://www.cescatherapeutics.com/.

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]